A recent review examining treatment aspirations for Arthritis patients undergoing therapy revealed that there are still major unmet needs in key areas such as pain, physical and mental function, fatigue and hence a need for new medications especially with orally available drugs.
There is also a very significant gap in the availability of well tolerated drugs that have immunomodulatory and analgesic activity that would be suitable for the treatment of early rheumatoid arthritis or undifferentiated arthritis, for which conventional DMARDs or biologics would be inappropriate.
More than 100 million Americans suffer from chronic pain at a cost of around $600B a year in medical treatments and lost productivity. Currently the number one public health issue in the USA.
Current treatments include opioids (cancer pain), nonsteroidal anti-inflammatory drugs or cyclo-oxygenase inhibitors (osteoarthritis), paracetamol (headache), anticonvulsants and tri-cyclic anti-depressants (AIDs, cancer or diabetes related neuropathies). All these treatments have limited efficacy and are associated with a variety of adverse events. Opioids also exhibit tolerance and therefore require increasing doses to maintain efficacy.
The increasing global burden of type 2 diabetes (T2D) makes this a disease of considerable concern at the individual patient level and also at the public health level given the direct health costs and indirect costs of loss of work productivity.
The life expectancy of a patient with T2D is likely to be reduced by up to 10 years as a result of having this condition. Given the need for multiple drug therapy to treat the condition, there is still a significant unmet medical need. Insulin is the most effective agent in reducing glucose levels: however, this efficacy does not come without the costs of increased hypoglycemia risk and weight gain. The challenge of combination therapy is the increased treatment complexity and side effects that can affect long-term adherence.
Novel compounds are needed to improve the safety and tolerability profile focused on overcoming known or hypothesized adverse effects of marketed agents. For example, agents that have limited gastrointestinal side effects, hypoglycemic risk, weight gain, fracture risk, and edema would be desirable.
Obesity is caused by a chronic imbalance between energy intake and expenditure. The growing problem of obesity, especially in children and adolescents, is a major public health concern. Obesity amplifies the risk of developing metabolic syndrome, which has devastating consequences, including decreased quality of life and shortened life span. Additionally, obese individuals have increased rates of depression. The pharmacologic treatment of obesity has been fraught with complications, including the inability to maintain weight loss, serious cardiovascular risks, and gastrointestinal symptoms.
Several pharmacologic therapies have been attempted to address the growing obesity epidemic. Unfortunately, the majority of these therapies have been associated with side effects that many would deem intolerable.
This could grow the Medical Marijuana market significantly by addressing key indications while tackling the issues associated with the current standards of care, offering people a safe orally available product without the side effects associated with current treatments, obesity epidemic. Unfortunately, the majority of these therapies have been associated with side effects that many would deem intolerable.